369 related articles for article (PubMed ID: 23509227)
1. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
Norata GD; Ballantyne CM; Catapano AL
Eur Heart J; 2013 Jun; 34(24):1783-9. PubMed ID: 23509227
[TBL] [Abstract][Full Text] [Related]
2. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
Sahebkar A; Watts GF
Cardiovasc Drugs Ther; 2013 Dec; 27(6):559-67. PubMed ID: 23913122
[TBL] [Abstract][Full Text] [Related]
3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
4. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy.
Yoon CH; Watson K
Ann Pharmacother; 2014 Feb; 48(2):238-49. PubMed ID: 24259646
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
6. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.
Stefanutti C; Morozzi C; Di Giacomo S
Curr Med Chem; 2012; 19(28):4861-8. PubMed ID: 22963620
[TBL] [Abstract][Full Text] [Related]
7. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
8. [PCSK9 inhibitors and dyslipidemias: an update on clinical evidence].
Norata GD
G Ital Cardiol (Rome); 2014 May; 15(5):301-5. PubMed ID: 25002170
[TBL] [Abstract][Full Text] [Related]
9. Lipid-Lowering Agents.
Hegele RA; Tsimikas S
Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
Cicero AF; Tartagni E; Ertek S
Expert Opin Biol Ther; 2014 Jun; 14(6):863-8. PubMed ID: 24661068
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
Lose JM; Dorsch MP; Bleske BE
Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
[TBL] [Abstract][Full Text] [Related]
13. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
Fazio S
Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
[TBL] [Abstract][Full Text] [Related]
14. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
[TBL] [Abstract][Full Text] [Related]
15. Novel nonstatin strategies to lower low-density lipoprotein cholesterol.
Davidson MH
Curr Atheroscler Rep; 2009 Jan; 11(1):67-70. PubMed ID: 19080731
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
17. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
18. Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.
Stein EA; Raal FJ
Curr Cardiol Rep; 2015 Nov; 17(11):104. PubMed ID: 26385394
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine in lipid-modifying therapy.
Tomlinson B; Lin CH; Chan P; Lam CW
Per Med; 2021 Mar; 18(2):185-203. PubMed ID: 33565320
[TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition - a novel mechanism to treat lipid disorders?
Banach M; Rizzo M; Obradovic M; Montalto G; Rysz J; Mikhailidis DP; Isenovic ER
Curr Pharm Des; 2013; 19(21):3869-77. PubMed ID: 23286435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]